17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations

US7538100B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Rolf Bohlmann · Berlin, DE
• Nikolaus Heinrich · Berlin, DE
• Rolf Jautelat · Haan, DE
• Jorg Kroll · Berlin, DE
• Orlin Petrov · Berlin, DE
• Andreas Reichel · Berlin, DE
• Jens Hoffmann · Mühlenbeck, DE
• Rosemarie Lichtner · Berlin, DE

Key dates

• Filing date: Jul 26, 2005
• Grant date: May 26, 2009
• Expiry date: Jul 26, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07J41/0072
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to 17α-alkyl-17β-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17β-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17α-alkyl-17β-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.